Phase I/II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme.

Trial Profile

Phase I/II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Vorinostat (Primary) ; Isotretinoin; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Mar 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Maximum tolerated doses from the phase I trial will be used in the multicentre adaptive randomised Phase II study in the near future, according to the 2015 ASCO abstract.
    • 02 Jun 2015 Phase I results in 55 patients enrolled between Nov 2007 and Mar 2012 presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top